Acute Respiratory FailureNCT03929055
Efficacy of High Velocity Nasal Insufflation
A study testing Physiological assesment in people with Acute Respiratory Failure and Diaphragmatic Function, run by University of Milan at 1 site in Italy.
Trial summary
The purpose of this study is to assess the effect of HFNC on esophageal pressure and diaphragmatic function in patients with acute respiratory failure Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Acute Respiratory Failure, Diaphragmatic Function, Esophageal Pressure
- What is being tested?
- Physiological assesment
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 25 participants
- Where
- 1 siteItaly
- Study dates
- 1 Jan 2018to 1 Jun 2021
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- patient with acute respiratory failure, not intubated, who require non invasive mechanical ventilation
Who cannot join
- patients in which it is not possible to place the esophageal catheter or it is not possible to detect the diaphragm by ultrasound or it is not possible to apply the nasal cannula device
Trial locations and contacts
1 site in 1 country.
Italy1 site, 1 recruiting
- Recruiting
ASST-Santi Paolo e Carlo, San Paolo Hospital
Milan, 20142
Davide Chiumello, +390281844020, chiumello@libero.it
About this study
Official title: Efficacy of High Velocity Nasal Insufflation Compared With Venturi Mask and Helmet CPAP in Acute Respiratory Failure
The purpose of this study is to assess the effect of HFNC on esophageal pressure and diaphragmatic function in patients with acute respiratory failure
Read the detailed description
In recent years, new devices that deliver totally conditioned gas through a nasal cannula at high flow have emerged as a safe and useful supportive therapy in many clinical situations. High flow nasal cannula (HFNC) supportive therapy is one such technique that exerts its potential benefits through a variety of mechanisms. In the last two decades, HFNC supportive therapy has emerged as a safe, useful therapy in patients with respiratory failure. Several mechanisms are known to contribute to oxygenation improvement and carbon dioxide reduction, which are the main potential benefits of using HFNC therapy. However, the exact contributions of each mechanism have not been conclusively established and these may, in fact, vary from one patient to another. Recently several clinical trials have analyzed the effectiveness of HFNC therapy in different clinical situations and have reported promising results such as the potential to improve clinical outcomes. However, the physiologic mechanisms underlying the clinical benefits of HFNC are still poorly understood in adult patients. Basic clinical monitoring during HFNC therapy demonstrated rapid improvement of oxygenation and reduction of dyspnea in comparison to a standard facial mask. Findings in other populations indicate that advanced respiratory monitoring might demonstrate other specific physiologic effects such as the reduction in inspiratory effort and increment in lung volume that may prevent respiratory muscle exhaustion and lower the tidal volume/end expiratory lung volume (EELV) ratio. Moreover, It has been hypothesized that the continuous administration of a very high flow of gas flushes the carbon dioxide (CO2) out of the upper respiratory airway, avoiding the re-inhalation of the previous exhaled gas. A randomized, crossover, experimental study with neonatal piglets with lung injury treated with continuous positive airway pressure (CPAP; minimal leak) or a HFNC with a high or low degree of leak around the nasal prongs showed that under both HFNC leak conditions PaCO2 decreased and oxygen arterial pressure (PaO2) increased with increasing flow. This effect of nasopharyngeal dead space washout was associated more with increases in flow rates than with increases in pressure. Thus, compared with the masks used with conventional oxygen delivery devices, nasal prongs reduce dead space.
Additionally, high velocity flows likely reduce inspiratory resistance and allow the patient to breathe from their dead space, rather than through it. This is how high velocity Nasal Insufflation helps reduce work of breathing, respiratory rate and assists in increasing alveolar ventilation efficiency.
The relative contribution of the patient's effort during assisted breathing is difficult to measure in clinical conditions, and the diaphragm, the major muscle of inspiratory function, is inaccessible to direct clinical assessment. Several methods have been used in the research setting to assess diaphragmatic contractile activity. Bedside ultrasonography, which is already crucial in several aspects of critically illness, has been recently proposed as a simple, non-invasive method of quantification of diaphragmatic contractile activity . Ultrasound can be used to determine diaphragm excursion which may help to identify patients with diaphragm dysfunction Ultrasonographic examination can also allow for the direct visualization of the diaphragm thickness in its zone of apposition. Thickening during active breathing has been proposed to reflect the magnitude of diaphragmatic effort, similarly to an ejection fraction of the heart. In spontaneously breathing patients, thickness fraction was shown to be positively related to tidal volume and thickness measurements during spontaneous breathing may be influenced by lung volume in a non-linear relationship, and diaphragmatic thickening was shown to be more pronounced above 50% of vital capacity. It seems reasonable to expect that the high flow nasal cannula may modify the thickness or diaphragm thickening and its excursion depend on the level of positive end expiration pressure generated. On the other hand, it could also happen that with a relevant increase in tidal volume the diaphragmatic excursion may remain constant. The most likely explanation is that a higher portion of the tidal volume (VT) is distributed to the non-dependent lung region due to better compliance of this area, as recently shown with electrical impedance tomography analysis. Another possible explanation is that patients' respiratory muscles could be over-assisted and the diaphragm may be passively displaced downward by simply improving gas exchange efficacy.
The aim of the present study is to compare the HFNC, Helmet continues positive airway pressure (CPAP) and venturi mask on the inspiratory effort, respiratory rate, gas exchange, level of dyspnea and diaphragmatic function evaluated by US in a group of patients with acute respiratory failure (ARF).
Inclusion and exclusion criteria The study has been submitted to our local ethics committee and patients will receive their written informed consent. All consecutive patients with acute respiratory failure presenting as respiratory rate higher than 25-30; Pao2 / oxygen inspiratory fraction (FiO2) ratio less than 300 supported with venturi mask at 30% Fio2. Patients will be exclude if there will be present one of the following conditions: PaO2/FiO2 less than 100; hemodynamic instability (mean arterial pressure lower than 60 mmHg after fluid challenge) and impossibility to insert the esophageal monitoring. Sample size calculation is based on the results of the study by Mauri, in which the application of HFNC at a similar flow rate to patients suffering from acute hypoxemic respiratory failure determined a reduction in esophageal pressure swing from 9.4+-4.1 to 7.9+-3.0. If the investigators hypothesize that a similar effect size is present in our patient population, a sample size of 25 patients will be necessary to achieve a level of significance of 0.05, with a 0.8 power, for a repeated-measures study design. Normally distributed variables are expressed as mean ± standard deviations and were analysed by a paired t-test. Non-normally distributed variables are expressed as medians and were compared by Wilcoxon's signed rank test. Correlations were analysed by Pearson's coefficient. A level of p\<0.05 (two-tailed) was considered statistically significant.
Experimental settings and Measurements A cross over study. Patients will enter in the three study phases with the same set clinical FiO2 for 20 minutes: standard Venturi oxygen mask with FiO2 regulated to achieve 90-04% of oxygen saturation (SpO2) with a flow rate of 35-40 Litters/minute (L/m); high velocity nasal insufflation (Precision Flow) with optimized gas flow; Helmet CPAP with positive end expiatory pressure (PEEP) set to reach the same esophageal swing obtained with HFNC. Using a small-bore nasal cannula the study will start with a flow rate set to 35 L/min, with a starting temperature between 35°C and 37°C and FIO2 at 1.0. Adjustments in flow (within the range of 25 L/min to 40 L/min) and temperature (typically between 35°C to 37°C) are made to alleviate respiratory distress and optimize comfort; FIO2 was titrated to maintain SpO2 at 90-94%.
At enrolment, the investigators will collect the patients' main demographics and clinical data. An esophageal balloon catheter will be placed in the esophagus, as demonstrated by the appearance of cardiac artefacts and appropriate negative swings of pressure tracings during inspiration. Esophageal pressure waveforms will be continuously recorded by a dedicated data acquisition system throughout the study. At each steps ultrasonography of the diaphragm will be performed using an ultrasound machine (GE Healthcare) equipped with a high-resolution 10-megahertz (MHz) linear probe and a 7.5-MHz convex phased-array probe. Images will be recorded for subsequent computer- assisted quantitative analysis performed by a trained investigator. The convex probe will be placed below the right costal margin along the mid-clavicular line, so that the ultrasound beam are perpendicular to the posterior third of the corresponding hemi-diaphragm, as previously described. Patients will be scanned along the long axis of the intercostal spaces, with the liver serving as an acoustic window. M-mode will then be used to display diaphragm excursion. Diaphragm thickness (DT) will be assessed in the zone of apposition of the diaphragm to the rib cage. The inferior border of the costophrenic sinus will be identified as the zone of transition from the artifactual representation of normal lung to the visualization of the diaphragm and liver. In this area, the diaphragm is observed as a three-layered structure: a non-echogenic central layer bordered by two echogenic layers, the peritoneum and the diaphragmatic pleurae.
- Being tested
- Physiological assesment
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Physiological assesmentDevice
- Arterial blood gas analysis.
- esophageal pressure variation during inspiration and expiration
- Arterial blood pressure, central venous pressure (CVP), heart rate.
- diaphragmatic contraction detected by ultrasound
| Study group | Role | What they receive |
|---|---|---|
| venturi mask | Active comparator | oxygen is delivered by venturi mask to achieve peripheral oxygen saturation of al least 92% Receives: Device: Physiological assesment |
| HFNC | Active comparator | HFNC is set to obtain the same oxygen fraction of venturi mask and flow of 40l/min Receives: Device: Physiological assesment |
| CPAP | Active comparator | Helmet CPAP is set to obtain the same esophageal pressure variation during HFNC step Receives: Device: Physiological assesment |
What is being measured
The primary outcome is the main question the study is designed to answer.
effects of HFNC on esophageal pressure variation
the esophageal pressure will be measure using an esophageal ballon catheter. A decrease in esophageal pressure variation during HFNC treatment compared with CPAP
Measured: one day
Secondary outcomes (1)
effect of HFNC on diaphragmatic function
the diaphragmatic function will be detected using the ultrasound. An improvement in diaphragmatic contractility function as detected by the increase in its thickness ratio is expected during HFNC treatment compared with CPAP
Measured: one day
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Apr 2019
- Study start1 Jan 2018
- Primary completion1 Jun 2021 (estimated)
- Study completion1 Jun 2021 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Acute Respiratory FailureStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Enrolment
- 25 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Milan
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Davide Chiumello, University of Milan
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03929055
- Sponsor's protocol ID
- HFNC
- Status last verified
- Nov 2020
- First submitted
- 20 Apr 2019
- Last updated
- 5 Nov 2020
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 5 Nov 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Efficacy of High Velocity Nasal Insufflation Compared With Venturi Mask and Helmet CPAP in Acute Respiratory Failure
- ClinicalTrials.gov ID
- NCT03929055
- Acronym / sponsor ID
- HFNC
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 25 participants (estimated)
- Lead sponsor
- University of MilanUniversity, hospital or other
- Study start
- 1 Jan 2018 (actual)
- Primary completion
- 1 Jun 2021 (estimated)
- Study completion
- 1 Jun 2021 (estimated)
- First posted
- 26 Apr 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to assess the effect of HFNC on esophageal pressure and diaphragmatic function in patients with acute respiratory failure
Detailed description
In recent years, new devices that deliver totally conditioned gas through a nasal cannula at high flow have emerged as a safe and useful supportive therapy in many clinical situations. High flow nasal cannula (HFNC) supportive therapy is one such technique that exerts its potential benefits through a variety of mechanisms. In the last two decades, HFNC supportive therapy has emerged as a safe, useful therapy in patients with respiratory failure. Several mechanisms are known to contribute to oxygenation improvement and carbon dioxide reduction, which are the main potential benefits of using HFNC therapy. However, the exact contributions of each mechanism have not been conclusively established and these may, in fact, vary from one patient to another. Recently several clinical trials have analyzed the effectiveness of HFNC therapy in different clinical situations and have reported promising results such as the potential to improve clinical outcomes. However, the physiologic mechanisms underlying the clinical benefits of HFNC are still poorly understood in adult patients. Basic clinical monitoring during HFNC therapy demonstrated rapid improvement of oxygenation and reduction of dyspnea in comparison to a standard facial mask. Findings in other populations indicate that advanced respiratory monitoring might demonstrate other specific physiologic effects such as the reduction in inspiratory effort and increment in lung volume that may prevent respiratory muscle exhaustion and lower the tidal volume/end expiratory lung volume (EELV) ratio. Moreover, It has been hypothesized that the continuous administration of a very high flow of gas flushes the carbon dioxide (CO2) out of the upper respiratory airway, avoiding the re-inhalation of the previous exhaled gas. A randomized, crossover, experimental study with neonatal piglets with lung injury treated with continuous positive airway pressure (CPAP; minimal leak) or a HFNC with a high or low degree of leak around the nasal prongs showed that under both HFNC leak conditions PaCO2 decreased and oxygen arterial pressure (PaO2) increased with increasing flow. This effect of nasopharyngeal dead space washout was associated more with increases in flow rates than with increases in pressure. Thus, compared with the masks used with conventional oxygen delivery devices, nasal prongs reduce dead space.
Additionally, high velocity flows likely reduce inspiratory resistance and allow the patient to breathe from their dead space, rather than through it. This is how high velocity Nasal Insufflation helps reduce work of breathing, respiratory rate and assists in increasing alveolar ventilation efficiency.
The relative contribution of the patient's effort during assisted breathing is difficult to measure in clinical conditions, and the diaphragm, the major muscle of inspiratory function, is inaccessible to direct clinical assessment. Several methods have been used in the research setting to assess diaphragmatic contractile activity. Bedside ultrasonography, which is already crucial in several aspects of critically illness, has been recently proposed as a simple, non-invasive method of quantification of diaphragmatic contractile activity . Ultrasound can be used to determine diaphragm excursion which may help to identify patients with diaphragm dysfunction Ultrasonographic examination can also allow for the direct visualization of the diaphragm thickness in its zone of apposition. Thickening during active breathing has been proposed to reflect the magnitude of diaphragmatic effort, similarly to an ejection fraction of the heart. In spontaneously breathing patients, thickness fraction was shown to be positively related to tidal volume and thickness measurements during spontaneous breathing may be influenced by lung volume in a non-linear relationship, and diaphragmatic thickening was shown to be more pronounced above 50% of vital capacity. It seems reasonable to expect that the high flow nasal cannula may modify the thickness or diaphragm thickening and its excursion depend on the level of positive end expiration pressure generated. On the other hand, it could also happen that with a relevant increase in tidal volume the diaphragmatic excursion may remain constant. The most likely explanation is that a higher portion of the tidal volume (VT) is distributed to the non-dependent lung region due to better compliance of this area, as recently shown with electrical impedance tomography analysis. Another possible explanation is that patients' respiratory muscles could be over-assisted and the diaphragm may be passively displaced downward by simply improving gas exchange efficacy.
The aim of the present study is to compare the HFNC, Helmet continues positive airway pressure (CPAP) and venturi mask on the inspiratory effort, respiratory rate, gas exchange, level of dyspnea and diaphragmatic function evaluated by US in a group of patients with acute respiratory failure (ARF).
Inclusion and exclusion criteria The study has been submitted to our local ethics committee and patients will receive their written informed consent. All consecutive patients with acute respiratory failure presenting as respiratory rate higher than 25-30; Pao2 / oxygen inspiratory fraction (FiO2) ratio less than 300 supported with venturi mask at 30% Fio2. Patients will be exclude if there will be present one of the following conditions: PaO2/FiO2 less than 100; hemodynamic instability (mean arterial pressure lower than 60 mmHg after fluid challenge) and impossibility to insert the esophageal monitoring. Sample size calculation is based on the results of the study by Mauri, in which the application of HFNC at a similar flow rate to patients suffering from acute hypoxemic respiratory failure determined a reduction in esophageal pressure swing from 9.4+-4.1 to 7.9+-3.0. If the investigators hypothesize that a similar effect size is present in our patient population, a sample size of 25 patients will be necessary to achieve a level of significance of 0.05, with a 0.8 power, for a repeated-measures study design. Normally distributed variables are expressed as mean ± standard deviations and were analysed by a paired t-test. Non-normally distributed variables are expressed as medians and were compared by Wilcoxon's signed rank test. Correlations were analysed by Pearson's coefficient. A level of p\<0.05 (two-tailed) was considered statistically significant.
Experimental settings and Measurements A cross over study. Patients will enter in the three study phases with the same set clinical FiO2 for 20 minutes: standard Venturi oxygen mask with FiO2 regulated to achieve 90-04% of oxygen saturation (SpO2) with a flow rate of 35-40 Litters/minute (L/m); high velocity nasal insufflation (Precision Flow) with optimized gas flow; Helmet CPAP with positive end expiatory pressure (PEEP) set to reach the same esophageal swing obtained with HFNC. Using a small-bore nasal cannula the study will start with a flow rate set to 35 L/min, with a starting temperature between 35°C and 37°C and FIO2 at 1.0. Adjustments in flow (within the range of 25 L/min to 40 L/min) and temperature (typically between 35°C to 37°C) are made to alleviate respiratory distress and optimize comfort; FIO2 was titrated to maintain SpO2 at 90-94%.
At enrolment, the investigators will collect the patients' main demographics and clinical data. An esophageal balloon catheter will be placed in the esophagus, as demonstrated by the appearance of cardiac artefacts and appropriate negative swings of pressure tracings during inspiration. Esophageal pressure waveforms will be continuously recorded by a dedicated data acquisition system throughout the study. At each steps ultrasonography of the diaphragm will be performed using an ultrasound machine (GE Healthcare) equipped with a high-resolution 10-megahertz (MHz) linear probe and a 7.5-MHz convex phased-array probe. Images will be recorded for subsequent computer- assisted quantitative analysis performed by a trained investigator. The convex probe will be placed below the right costal margin along the mid-clavicular line, so that the ultrasound beam are perpendicular to the posterior third of the corresponding hemi-diaphragm, as previously described. Patients will be scanned along the long axis of the intercostal spaces, with the liver serving as an acoustic window. M-mode will then be used to display diaphragm excursion. Diaphragm thickness (DT) will be assessed in the zone of apposition of the diaphragm to the rib cage. The inferior border of the costophrenic sinus will be identified as the zone of transition from the artifactual representation of normal lung to the visualization of the diaphragm and liver. In this area, the diaphragm is observed as a three-layered structure: a non-echogenic central layer bordered by two echogenic layers, the peritoneum and the diaphragmatic pleurae.
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| venturi mask | Active comparator | Device: Physiological assesmentoxygen is delivered by venturi mask to achieve peripheral oxygen saturation of al least 92% |
| HFNC | Active comparator | Device: Physiological assesmentHFNC is set to obtain the same oxygen fraction of venturi mask and flow of 40l/min |
| CPAP | Active comparator | Device: Physiological assesmentHelmet CPAP is set to obtain the same esophageal pressure variation during HFNC step |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- patient with acute respiratory failure, not intubated, who require non invasive mechanical ventilation
Key exclusion criteria (1 listed)
- patients in which it is not possible to place the esophageal catheter or it is not possible to detect the diaphragm by ultrasound or it is not possible to apply the nasal cannula device
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Physiological assesment1. Arterial blood gas analysis. 2. esophageal pressure variation during inspiration and expiration 3. Arterial blood pressure, central venous pressure (CVP), heart rate. 4. diaphragmatic contraction detected by ultrasound | Device | CPAP, HFNC, venturi mask |
Primary outcome
effects of HFNC on esophageal pressure variation
Time frame: one day
the esophageal pressure will be measure using an esophageal ballon catheter. A decrease in esophageal pressure variation during HFNC treatment compared with CPAP
1 secondary outcome
effect of HFNC on diaphragmatic function
Time frame: one day
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Nov 2020.
Related trials for Acute Respiratory Failure
Enrolling by invitation
Personalized Ventilator Settings for Patients on ECMO
Acute Respiratory Distress Syndrome (ARDS), Extracorporeal Membrane Oxygenation
Not yet recruiting
Regional Lung Ventilation During Prone Position in in Intubated Children
Pediatric Acute Respiratory Failure
Not yet recruiting
Influence of Patient Positioning During Nasal Lavage
Acute Upper Respiratory Tract Infections, Nasal Obstruction
Recruiting
WIN Ratio Analysis to Determine a Strategy of Non- Invasive SUpport for Respiratory Failure in the EmeRgency Department
Acute Hypoxic Respiratory Failure, Acute Respiratory Distress Syndrome (ARDS)
Not yet recruiting
ICU-SUCCEED for Survivors of Acute Respiratory Failure and Their Caregivers
Acute Respiratory Failure, Critical Illness
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Physiological assesment in people with Acute Respiratory Failure and Diaphragmatic Function, run by University of Milan at 1 site in Italy.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 5 Nov 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
effects of HFNC on esophageal pressure variation (time frame: one day). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Nov 2020.